males and females

age 40-60 years

bmi< or = 35 kg/m2

diabetic subjects with hba1c concentrations of < or = 8%.

diabetic subjects will be either on diet and lifestyle therapy alone, or monotherapy with metformin or sulphonylureas (except glyburide).

all diabetic subjects should be on stable dose oral agent therapy for 3 months prior to enrollment.

subjects with cerebrovascular or peripheral vascular disease.

subjects with suspected or overt autonomic neuropathy.

diabetic subject on thiazolidinediones, insulin, glp-1 based therapies (exenatide or sitagliptin), alpha-glucosidase inhibitors, glyburide or combination antidiabetic drug therapies.

diabetics with microalbuminuria.